The results indicated that QD-Apt(Dox) could differentially bind to prostate specific membrane antigen(PSMA)-expressing LNCaP cells instead of the PSMA-negative PC3 prostate adenocarcinoma cell lines due to the aptamer selectively binding to PSMA. This evidence concerns the gene FOLH1 and prostate adenocarcinoma.